trending Market Intelligence /marketintelligence/en/news-insights/trending/VYZP6mCy8oE2L5b0GgF-lA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK's NICE recommends Medtronic's device to detect abnormal heartbeat

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


UK's NICE recommends Medtronic's device to detect abnormal heartbeat

The U.K. National Institute for Health and Care Excellence recommended Medtronic PLC's Reval LINQ heart monitor for routine adoption on the National Health Service.

The agency gave the nod to the implantable cardiac monitor to identify people with atrial fibrillation after a stroke with no identified cause, known as cryptogenic stroke, or an ischemic attack — a mini-stroke caused by temporary loss of blood supply to the brain.

Reval LINQ is implanted under the skin in the chest to track the heart's activity over a long period of time, transmitting data back to the patient's doctor via a mobile phone network.

Cryptogenic stroke patients have a high chance of recurrent stroke and require an accurate diagnosis to receive preventive therapy.

According to data presented to the U.K. body, atrial fibrillation after a cryptogenic stroke was detected in five times more people using a Reveal monitor for six months compared with people who did not have the device implanted.

Clinical experts have noted that noninvasive ECG-monitoring should be carried out prior to using the Reveal LINQ, NICE said in its news release.

The cost of the Reveal LINQ is £1,800 plus the cost of implanting the device. In assessing the device, it was assumed that people with an implantable cardiac monitor would have one face-to-face follow up a month after the procedure and then would be remotely monitored.

NICE diagnostic guidance is nonmandatory, but it is considered best practice for the NHS to implement it.